BARCELONA, Spain, Sept. 20 /PRNewswire/ -- Talecris Biotherapeutics GmbH announced yesterday the recipients of the 2010 European alpha1-antitrypsin Laurell's Training Awards (eALTA). The annual awards, sponsored by Talecris, provide two fellowships of 50,000 euros to young investigators whose research aims to enhance the understanding and treatment of alpha1-antitrypsin deficiency (AAT deficiency). AAT deficiency is a rare, genetic condition in which low levels of the alpha-1 protein can result in emphysema and liver disease.
The 2010 recipients of eALTA are Sandra Pelz, postgraduate research fellow at the Martin-Luther-University in Halle-Wittenberg, Germany and Dr Adriana Ordonez, post-doctoral research fellow at the Cambridge Institute for Medical Research Wellcome Trust. Pelz and Ordonez were presented with the awards during the 2010 European Respiratory Society (ERS) Annual Congress in Barcelona at a Talecris-sponsored symposium. The symposium also featured research presentations by the 2009 eALTA award winners.
Pelz and Ordonez's research projects will both explore potential new therapies to treat AAT deficiency. Pelz's research project will use a mouse model to investigate the potential use of stem cell-derived liver cells, known as hepatocytes, to correct the genetic defect that gives rise to liver disease associated with AAT deficiency. Ordonez's project will study the mechanism by which small molecule inhibitors – a specific class of drug – can block the Alpha-1 protein from abnormally folding and accumulating in the endoplasmic reticulum of hepatocytes.
"Research initiatives such as eALTA not only increase our understanding of the disease, but they also help stimulate the interest and commitment of early career scientists and clinicians who represent the future of research and new treatments for the Alpha-1 community," said Claus Vogelmeier, Professor for Internal and Respiratory Medicine and Chair of the independent e
|SOURCE Talecris Biotherapeutics|
Copyright©2010 PR Newswire.
All rights reserved